Factors influencing the outcome of bone marrow transplants using unrelated donors

Immunological Reviews

Volumn 157, Issue , 1997, Pages 153-166

  Madrigal, J Alejandro ^a,b   Scott, Iain ^a   Arguello, Rafael ^a   Szydlo, Richard ^b   Little, Ann Margaret ^a   Goldman, John M ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; DNA; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; MINOR HISTOCOMPATIBILITY ANTIGEN; XOMAZYME;

AGE; ALLELE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; DNA DETERMINATION; DNA POLYMORPHISM; GENDER; GENE LOCUS; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INFECTION; LABORATORY TEST; MORBIDITY; MORTALITY; ORGAN DONOR; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED KINGDOM;

BONE MARROW TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LIVING DONORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0030801514     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00980.x     Document Type: Review

References (120)

1. Thomas ED. Karnofsky Memorial Lecture: Marrow transplantation for malignant diseases. J Clin Oncol 1983;1:517-531.
2. O'Reilly RJ. Allogeneic bone marrow transplantation: current status and future directions. Blood 1983;62:941-964.
3. Bortin MM, Gale RP, Kay HE, Rimm AA. Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality. JAMA 1983;249:1166-1175.
4. Goldman JM, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986;314:202-207.
5. Gratwohl A, Hermans J, Baldomero H. For the European Group for Blood and Marrow Transplantation. Blood and marrow transplantation activity in Europe 1995. Bone Marrow Transplant 1997;19:407-419.
6. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
7. Hehlmann R, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064-4077.
8. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-692.
9. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069.
10. Alimena G, et al. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988;72:642-647.
11. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-1397.
12. Goldman JM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Int Med 1988;108:806-814.
13. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993;82:1954-1956.
14. Snyder DS, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994;84:1672-1679.
15. Bortin MM, Rimm AA. Increasing utilization of bone marrow transplantation. II. Results of the 1985-1987 survey. Transplantation 1989;48:453-458.
16. Horowitz SD, Bach FH, Groshong T, Hong R, Yunis EJ. Treatment of severe combined immunodeficiency with bone-marrow from an unrelated, mixed-leucocyte-culture-non-reactive donor. Lancet 1975;2:431-433.
17. O'Reilly R, et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977;197:1311-1318.
18. Burnett AK. The treatment of acute leukaemia. Lancet 1997;349:270-275.
19. The Westminster Hospital's Bone Marrow Transplant Team. Bone-marrow transplant from an unrelated donor for chronic granulomatous disease. Lancet 1977;1:210-213.
20. Speck B, Zwaan FE, van Rood JJ, Eernisse JG. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HL-A-identical unrelated donor. Transplantation 1973;16:24-28.
21. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565-567.
22. Hows JM, et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 1986;68:1322-1328.
23. McGlave P, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993;81:543-550.
24. Hansen JA. HLA and marrow transplants from unrelated donors. Exp Hematol 1993;22:677 (Abstract).
25. Marks DI, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993;119:207-214.
26. Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1993;12:371-380.
27. Atkinson K, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-2464.
28. Gale RP, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987;67:397-406.
29. Bacigalupo A, et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). Bone Marrow Transplant 1993;12:443-448.
30. Ash RC, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990;322:485-494.
31. Howard MR, et al. Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. Transplantation 1990;49:547-553.
32. McGlave P, Beatty P, Ash R, Hows J. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990;75:1728-1732.
33. Rufer N, et al. High-resolution histocompatibility testing of a group of sixteen B44-positive, ABDR serologically matched unrelated donor-recipient pairs. Analysis of serologically undisclosed incompatibilities by cellular techniques, isoelectrofocusing, and HLA oligotyping. Hum Immunol 1993;38:235-239.
34. Tiercy JM, et al. Selection of unrelated donors for bone marrow transplantation is improved by HLA class II genotyping with oligonucleotide hybridization. Proc Natl Acad Sci USA 1991;88:7121-7125.
35. Goulmy E, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-285.
36. van Rood J, van Leeuwen A, Keuning J, van Oud B, Alblas A. The serological recognition of the human MLC determinants using a modified cytotoxicity technique. Tissue Antigens 1975;5:73-79.
37. Bodmer JG, et al. Nomenclature for factors of the HLA system, 1995. Tissue Antigens 1995;46:1-18.
38. Dupont B, Braun DW, Yunis EJ, Carpenter CB. HLA-D by cellular typing. In: Terasaki PI, ed. Histocompatibility testing. Los Angeles: UCLA; 1980. p. 229-267.
39. Bodmer JG, et al. Nomenclature for factors of the HLA system, 1996. Tissue Antigens 1997;49:297-321.
40. Fleischhauer K, Kernan N, O'Reilly R, Dupont B, Yang S. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 1990;323:1818-1822.
41. Jordan F, et al. Comparison of HLA-DRB1 typing by DNA-RFLP, PCR-SSO and PCR-SSP methods and their application in providing matched unrelated donors for bone marrow transplantation. Tissue Antigens 1995;45:103-110.
42. Parham P, Adams EJ, Arnett KL. The origins of HLA-A,B,C polymorphism. Immunol Rev 1995;143:141-180.
43. Krausa P, et al. Genetic polymorphism within HLA-A*02:significant allelic variation revealed in different populations. Tissue Antigens 1995;45:223-231.
44. Cereb N, Maye P, Lee S, Kong Y, Yang SY Locus-specific amplification of HLA class I genes from genomic DNA: locus-specific sequences in the first and third introns of HLA-A, -B, and -C alleles. Tissue Antigens 1995;45:1-11.
45. Tiercy J-M, Grundschober C, Jeannet M, Mach BA. A comprehensive HLA-DRB, -DQB, and -DPB oligotyping procedure by hybridization with sequence-specific oligonucleotide probes. In: Hui KM, Bidwell JL, eds. Handbook of HLA typing techniques. Boca Raton: CRC Press Inc: 1993. p. 117-147.
46. Bidwell JL. Applications of the polymerase chain reaction to HLA class II typing. Vox Sang 1992;63:81-89.
47. Krausa P Bodmer JG, Browning MJ. Defining the common subtypes of HLA A9, A10, A28 and A19 by use of ARMS/PCR. Tissue Antigens 1993;42:91-99.
48. Allen M, Liu L, Gyllensten U. A comprehensive polymerase chain reaction-oligonueleotide typing system for the HLA class I A locus. Hum Immunol 1994;40:25-32.
49. Gao X, Jakobsen IB, Serjeantson SW. Characterization of the HLA-A polymorphism by locus-specific polymerase chain reaction amplification and oligonucleotide hybridization. Hum Immunol 1994;41:267-279.
50. Clay TM, Bidwell JL, Howard MR, Bradley BA. PCR-fingerprinting for selection of HLA matched unrelated marrow donors. Collaborating centres in the IMUST Study Lancet 1991;337:1049-1052.
51. Tong JY, Hammad A, Rudert WA, Trucco M, Hsia S. Heteroduplexes for HLA DQB1 identity of family members and kidney donor-recipient pairs. Transplantation 1994;57:741-745.
52. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-879.
53. Blasczyk R, Hahn U, Wehling J, Huhn D, Salama A. Complete amplification followed by direct sequencing or single-strand conformation polymorphism analysis. Tissue Antigens 1995;46:86-95.
54. Petersdorf EW, Hansen JA. A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing. Tissue Antigens 1995;46:73-85.
55. Blasczyk R, Hahn U, Wehling J, Huhn D, Salama A. Complete subtyping of the HLA A locus by sequence-specific amplification followed by direct sequencing or single-strand conformation polymorphism analysis. Tissue Antigens 1995;46:86-95.
56. Rozemuller EH, Tilanus MGJ. A computerized method to predict the discriminatory properties for class II sequenced based typing. Hum Immunol 1996;46:27-34.
57. Madrigal JA, et al. High resolution HLA class I and II typing for unrelated bone marrow donors. Eur J Immunogenet 1997;24:70 (Abstract).
58. Arguello R, Avakian H, Goldman JM, Madrigal JA. A novel method for simultaneous high resolution identification of HLA-A, HLA-B and HLA-Cw alleles. Proc Natl Acad Sci USA 1996;93:10961-10965.
59. Keever CA, et al. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant 1994;14:137-145.
60. Baxter-Lowe L, Eckels DD, Ash R, Casper J, Hunter JB, Gorski J. The predictive value of HLA-DR oligotyping for MLC responses. Transplantation 1992;53:1352-1357.
61. Termijtelen A, et al. Oligonucleotide typing is a perfect tool to identify antigens stimulatory in the mixed lymphocyte culture. Hum Immunol 1991;31:241-245.
62. Kaminski E, Hows J, Goldman J, Batchelor R. Optimising a limiting dilution culture system for quantitating frequencies of alloreactive cytotoxic T lymphocyte precursors. Cell Immunol 1991;137:88-95.
63. Kaminski E, et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989;48:608-613.
64. Schwarer AP, et al. Frequency of antirecipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993;341:203-205.
65. Roosnek E, et al. The frequency of pretransplant donor cytotoxic T cell precursors with anti-host specificity predicts survival of patients transplanted with bone marrow from donors other than HLA-identical siblings. Transplantation 1993;56:691-696.
66. Arguello R, et al. Cytotoxic T lymphocyte precursor frequency (CTLpf) analysis highlights the need for better matching in the selection of unrelated bone marrow donors. Bone Marrow Transplant 1995;15:248 (Abstract).
67. Kaminski ER, et al. Cytotoxic T lymphocyte precursor (CTL-p) frequency analysis in unrelated donor bone marrow transplantation: two case studies. Bone Marrow Transplant 1991;8:47-50.
68. Zhang L, Rinke de Wit TF, Li S, van Rood JJ, Claas FH. Subtypes of HLA-A1 defined on the basis of CTL precursor frequencies. Hum Immunol 1990;27:80-89.
69. Schwarer AP, et al. Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation. Transplantation 1994;58:1198-1203.
70. Tiercy JM, et al. Replacement of HLA class II serology by the HLA-DR microtitre plate oligotyping assay: a one-year experience in unrelated bone marrow donor selection. Br J Haematol 1993;85:417-418.
71. Rufer N, et al. HLA-B35-subtype mismatches in ABDR serologically matched unrelated donor-recipient pairs. Hum Immunol 1994;41:96-101.
72. Tiercy JM, Djavad N, Rufer N, Speiser DE, Jeannet M, Roosnek E. Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. Hum Immunol 1994;41:207-215.
73. Scott I, et al. How well do we have to match in BMT? Eur J Immunogenet 1995;22:36 (Abstract).
74. Davies SM, et al. Comparison of engraftment in recipients of matched sibling of unrelated donor marrow allografts. Bone Marrow Transplant 1994;13:51-57.
75. Gajewski JL, Ho WG, Feig SA, Hunt L, Kaufman N, Champlin RE. Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 1990;50:244-249.
76. Kernan N, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602.
77. Beatty PG, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993;81:249-253.
78. Spencer A, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995;86:3590-3597.
79. Petersdorf EW. Association of HLA-C disparity with graft failure after marrow-transplantation from unrelated donors. Blood 1997;89:1818-1823.
80. Davies SM, et al. Unrelated donor bone marrow transplantation : influence of HLA A and B incompatibility on outcome. Blood 1995;86:1636-1642.
81. Madrigal JA, et al. Distinctive HLA-A,B antigens of black populations formed by interallelic conversion. J Immunol 1992;149:3411-3415.
82. Petersdorf EW, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995;86:1606-1613.
83. Hansen JA. Unrelated donor marrow-transplants for patients with chronic myeloid leukemia. Blood 1995;123:479 (Abstract).
84. Barnardo M, et al. A correlation between HLA-C matching and donor antirecipient CTL precursor frequency in bone marrow transplantation. Transplantation 1996;61:1420-1423.
85. Bunce M, Welsh KI. Rapid DNA-typing for HLA-C using sequence-specific primers (PCR-SSP):identification of serological and non-serologically defined HLA-C alleles including several new alleles. Tissue Antigens 1994;43:7-17.
86. Speiser DE, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996;87:4455-4462.
87. Lanier LL, Gumperz JE, Parham P, Melero I, Lopez-Botet BM, Phillips JH. The NKB1 and HP-3E4 NK cells receptors are structurally distinct glycoproteins and independently recognize polymorphic HLA-B and HLA-C molecules. J Immunol 1995;154:3320-3327.
88. Colonna M, et al. Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci USA 1992;89:7983-7985.
89. Petersdorf EW et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996;93:15358-15363.
90. Santamaria P, et al. Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. Blood 1994;83:280-287.
91. Pawelec G, Ehninger G, Schmidt H, Wernet P. HLA-DP matching and graft-versus-host disease in allogeneic bone marrow transplantation. Transplantation 1986;41:558-560.
92. Petersdorf EW, et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood 1993;81:1923-1932.
93. Potolicchio I, Brookes PA, Madrigal JA, Lechler RI, Sorrentino R. HLA-DPB1 mismatch at position 69 is associated with high helper T lymphocyte precursor frequencies in unrelated bone marrow transplant pairs. Transplantation 1996;62:1347-1352.
94. Brown JH, et al. 3-Dimensional structure of the human class II histocompatibility antigens HLA-DR1. Nature 1993;364:33-39.
95. Fussell ST, Donnellan M, Cooley MA, Farrell C. Cytotoxic T lymphocyte precursor frequency does not correlate with either the incidence or severity of graft-versus-host disease after matched unrelated donor bone marrow transplantation. Transplantation 1994;57:673-676.
96. Pei J. Analysis of correlation between alloimmune cytotoxic responses generated from unrelated donors and severity of acute graft-versus-host disease. Hum Immunol 1993;37(Suppl 1):87 (Abstract).
97. Spencer A, et al. Cytotoxic T lymphocyte precursor frequency analysis in bone marrow transplantation with volunteer unrelated donors. Transplantation 1995;59:1302-1308.
98. De Bueger M, Bakker A, Bontkes H, van Rood J, Goulmy E. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD. Bone Marrow Transplant 1993;11:363-368.
99. Behar E, et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 1996;334:286-291.
100. den Haan J, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-1480.
101. Wang W, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-1590.
102. van Lochern E, van der Keur M, Mommaas AM, de Gast GC, Goulmy E. Functional expression of minor histocompatibility antigens on peripheral blood dentritic cells and epidermal Langerhans' cells. Transpl Immunol 1997 (In press).
103. Beatty PG, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-771.
104. Szydlo R. Results of allogeneic bone marrow transplants for leukaemia using donors other than HLA-identical siblings. J Clin Oncol 1997 (In press).
105. Horowitz MM, Bortin MM. The role of registries in evaluating the results of bone marrow transplantation. In: Treleaven J, Barrett J, eds. Bone marrow transplantation in practice. Edinburgh: Churchill Livingstone; 1992, p. 367-377.
106. Cleaver S. The Anthony Nolan Research Centre and other matching registries. In: Treleaven J, Barrett J, eds. Bone marrow transplantation in practice. Edinburgh: Churchill Livingstone; 1992. p. 361-366.
107. Hansen J, McCullough J. Alternative donors-unrelated donor BMT. In: Champlin RE, Gale RP, eds. New strategies in bone marrow transplantation. New York: Wiley-Liss; 1991. p. 453-457.
108. Zwaan FE, Hermans J. Bone marrow transplantation for leukemia - European results in 264 cases. Exp Hematol 1982;10:64-69.
109. Gratwohl A, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myclogenous leukemia. Blood 1995;86:813-818.
110. Bortin MM, Gale RP, Rimm AA. Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. JAMA 1981;245:1132-1139.
111. Gluckman E, Barrett AJ, Arcese W, Devergie A, Degoulet P. Bone marrow transplantation in severe aplastic anaemia: a survey of the European Group for Bone Marrow Transplantation. Br J Haematol 1981;49:165-173.
112. Lajtha LG, Schofield R. Regulation of stem cell renewal and differentiation: possible significance in aging. Adv Gerontol Res 1971;3:131-146.
113. Botnick LE, Hannon EC, Obbagy J, Hellman S. The variation of hematopoietic stem cell self-renewal capacity as a function of age: further evidence for heterogenicity of the stem cell compartment. Blood 1982;60:268-271.
114. Manch P, Botnick L, Hannon E, Obbagy J, Hellman S. Decline in bone marrow proliferative capacity as a function of age. Blood 1982;60:245-252.
115. Oakhill A. Unrelated donor bone marrow transplantation for children with relapsed acute lymphobastic leukaemia in second complete remission. Br J Haematol 1996;94:574-578.
116. Ash RC, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T-cell depletion. Bone Marrow Transplant 1991;7:443-452.
117. Meyers J, Flournoy N, Thomas E. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-488.
118. Weiden P. Graft-v-host disease following blood transfusions. Arch Intern Med 1984;144:1557-1558.
119. van Bekkum DW. Graft-versus-host-disease. In: van Bekkum DW, Lowenberg B, eds. Bone marrow transplantation: biological mechanisms and clinical practice. New York: Marcel Dekker; 1985. p. 147-167.
120. Bakker JT. A new development on the Internet: bone marrow donors worldwide. EFI Newsletter 1996;14 (December).